Trial Profile
A retrospective study evaluating efficacy of anti-PD-1 antibodies in melanoma patients with brain metastases.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Oct 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- 06 Oct 2017 New trial record